DSIP
NeuroprotectionCognitive performance and neurological recovery applications of DSIP centre on its relationship to cerebral perfusion, BDNF and NGF signalling, and the gut-brain inflammatory axis. A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience. A 9-residue neuropeptide (sleep), DSIP is investigated in nootropic, post-injury, and chronic-neuroinflammation contexts; the cognitive endpoints accumulate across 4-8 weeks rather than appearing acutely.
Key Takeaways
Cognitive lens: DSIP acts as a restorative compound rather than a stimulant for cognitive endpoints. CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects. Mechanism: Mechanism remains incompletely characterised. Neuro dose: 100-500 mcg 1x daily before sleep via subq/intranasal; cognitive effects accumulate across 4-8 weeks. Cognitive stack partners: Semax, Selank, Semax + Selank Blend.
DSIP's neurological relevance starts with how the compound reaches the central nervous system. Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. Direct blood-brain barrier transport is rarely the dominant route for peptide compounds; vagal-afferent gut-brain signalling and effects on cerebral vasculature where the barrier is locally compromised typically produce the CNS phenotype. The detail follows.
Inflammation and neurological recovery
One of the most replicated effects across compounds in DSIP's class (Neuropeptide (sleep)) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. DSIP's contribution operates on the same axis at 100-500 mcg per dose.
Central nervous system access
DSIP reaches the central nervous system through one or more of three documented routes: direct blood-brain barrier transport, vagal-afferent signalling via the gut-brain axis, and direct action on cerebral vasculature in regions where the barrier is locally compromised. The compound's subq/intranasal route(s) and ~7 min plasma; CNS effects longer half-life set the timeline for CNS exposure. Mechanism remains incompletely characterised. The CNS-relevant phenotype that emerges from this mechanism is the substrate of the cognitive effects described below.
Receptor pharmacology and selectivity profile
DSIP's receptor-level pharmacology determines its selectivity profile and its overlap with companion peptides. Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. The selectivity (or lack thereof) for the principal target relative to off-target receptors is the basis for both the clinical phenotype and the side-effect profile. In stack design this matters: pairing DSIP with peptides engaging the same primary receptor produces competition rather than synergy.
Where DSIP is used for long-covid cognitive recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
Post-TBI Recovery is one of the more-reported subjective benefits of DSIP across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.
For anxiety, DSIP is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.
Where DSIP is used for serotonin modulation, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-500 mcg | 4–6 weeks initial cycle |
| Neuroprotection focus | SubQ | 100-500 mcg | 1x daily before sleep |
| Maintenance phase | SubQ | 70-500 mcg | Ongoing with periodic pauses |
Dose timing for DSIP is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
DSIP stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.
- DSIP + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with DSIP's mechanism in cognitive / neurological protocols.
- DSIP + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with DSIP's mechanism in cognitive / neurological protocols.
- DSIP + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with DSIP's mechanism in cognitive / neurological protocols.
- DSIP + LL-37: Amphipathic α-helical peptide cleaved from hCAP-18 by proteinase 3. Pairs naturally with DSIP's mechanism in cognitive / neurological protocols.
Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants.
Lens-specific safety considerations for cognitive / neurological use of DSIP: Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | Neuroprotection |
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent |
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder |
| Pinealon | Khavinson tripeptide (pineal-derived) | Short plasma; durable tissue effects | A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models |
Does DSIP cross the blood-brain barrier?
Is DSIP appropriate alongside SSRIs or other psychiatric medications?
Can DSIP be stacked with other nootropics?
How long until I notice cognitive effects?
What is the standard dosing protocol for DSIP?
How does DSIP compare to Semax and Selank?
Start a DSIP Protocol
Alukard provides physician-supervised cognitive protocols with GMP-certified DSIP and GMP-certified compounds and comprehensive neurological assessments.
Get ProtocolQuick Facts
- Molecular weight
- 848 Da
- Sequence length
- 9 aa
- Half-life
- ~7 min plasma; CNS effects longer
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Preclinical + small human series
Stack Partners
All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Cognitive / Neurological Protocol for DSIP
Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.
HIPAA Compliant · GMP Certified · Physician Supervised